Topotecan hydrochloride

Research use only, not for human use.

Topotecan HCl (SKF 104864A; NSC 609669) is the first topoisomerase I-directed cytotoxic agent to enter clinical trials in the United States.

Topotecan HCl (SKF 104864A; NSC 609669) is the first topoisomerase I-directed cytotoxic agent to enter clinical trials in the United States. (In Vitro):Topotecan Hydrochloride (SKF 104864A Hydrochloride) obviously inhibits proliferation of not only human glioma cells but also glioma stem cells (GSCs) in a dose- and time-dependent manner. According to the IC50 values at 24 h, 3 μM of Topotecan Hydrochloride is selected as the optimal administration concentration. In addition, Topotecan Hydrochloride induces cell cycle arrest in G0/G1 and S phases and promoted apoptosis. Results show that the cell viability is inhibited by Topotecan Hydrochloride in a dose-dependent manner. 2, 20 and 40 μM of Topotecan Hydrochloride obviously inhibits the cell viability compared with the control groups. The IC50 values of Topotecan Hydrochloride at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95±0.24 μM of GSCs-U87. Thus 3 μM of Topotecan Hydrochloride is selected as the optimal administration concentration in the subsequent experiments. (In Vivo):NUB-7 metastatic model, the animals belonging to all the 4 groups are sacrificed after 14 days treatment. Compared with the control, Low dose metronomic (LDM) Topotecan Hydrochloride and TP+Pazopanib (PZ) liver weights are significantly lower in TP+PZ-treated animals, compared with PZ. Microscopic tumors are visible in the livers of mice belonging to all the groups except TP+PZ confirming the ability of Topotecan Hydrochloride+PZ to control liver metastasis. In a previous dose-response study, the daily dose of oral metronomic Topotecan Hydrochloride (0.5, 1.0, and 1.5 mg/kg) causes greater reduction in microvascular density compared with weekly maximum-tolerated dose regimen (7.5 and 15 mg/kg) in an ovarian cancer model, but the mice treated with 1.5 mg/kg daily, oral Topotecan Hydrochloride show decreased food intake, and a lesser antitumor effect.

——

——

Hycamtin | NSC 609669 | SKF 104864A

Cell Cycle/DNA Damage

Topoisomerase

Topo I (DU-145 Luc cells)| Topo I (MCF-7 Luc cells)

Cancer

——

119413-54-6

457.92

C23H24ClN3O5

>98% (HPLC)

Water: 92 mg/mL (200.91 mM); DMSO: 92 mg/mL (200.91 mM)

CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=C(C5=C4)CN(C)C)O)O.Cl

——

(-20℃)

With Ice Pack

≥ 2 years